Fiasp (fast-acting insulin aspart) / Novo Nordisk - LARVOL DELTA

Glycemic and safety outcomes of the insulin-only bionic pancreas in older adults and individuals with impaired awareness of Hypoglycemia: a post hoc analysis of a randomized pivotal trial. (PubMed, Diabetes Res Clin Pract) - P=N/A | "In high-risk, clinically vulnerable populations, the BP system significantly improved glycemic control while maintaining safety parity with respect to hypoglycemia risk, providing a resilient therapeutic alternative for vulnerable cohorts."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Monomeric Insulin Analog and Stabilizing Excipient Enabled Ultrafast Insulin Formulation. (PubMed, Adv Mater) - "In a porcine model of diabetes, monomeric HALQ exhibits significantly accelerated absorption and a shorter duration of action than the ultrarapid insulin aspart Fiasp...Addition of clinically used absorption enhancers further accelerates its pharmacokinetic profile, producing a faster time-to-peak and reduced exposure relative to ultrarapid insulin lispro Lyumjev in this animal model...These simulations suggest the potential utility of achieving a step-change in the speed of insulin therapy. These findings demonstrate that monomer-stabilizing excipients enable next-generation ultrafast insulin formulations with the potential to improve glycemic control in diabetes."

Journal • Diabetes • Metabolic Disorders

(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "(Ultra-)short-acting insulin analogues may result in little to no difference in glycaemic control, non-severe hypoglycaemia and treatment adherence at short-term follow-up, but some agents may reduce severe/serious hypoglycaemia and DKA. We are uncertain about the effects of these insulins on mild to moderate nocturnal hypoglycaemia and quality of life. There were no long-term follow-up data."

Clinical • Journal • Retrospective data • Review • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus • IL1R1

CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial (clinicaltrials.gov) - P=N/A | N=44 | Not yet recruiting | Sponsor: Hallym University

New trial • Diabetes • Metabolic Disorders • Otorhinolaryngology • Type 2 Diabetes Mellitus

Using Degludec, Faster Aspart, and Other Newer Insulin Analogs in Pregnancy (ADA 2026) - No abstract available

Metabolic Disorders

Effects of clinical training on compliance with standard precautions among nursing students: a quasi-experimental study. (PubMed, BMC Med Educ) - "The findings of this study highlight the importance of designing a clinical training program that provides students with opportunities to experience nursing skills and procedures that require strict adherence to standard precautions. Nursing academics must address strategies in the nursing curriculum that will enable nursing students to transfer knowledge of infection prevention and control practices to clinical education."

Compliance • Journal • Infectious Disease

Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy? (PubMed, Diabet Med) - "In this randomised crossover study of children and adolescents with T1D achieving glycaemia close to target on CSII, switching from SIA to FIA does not improve TIR. The absence of improvement across CGM-derived metrics suggests that FIA does not meaningfully enhance glycaemic outcomes in this clinical setting."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor (clinicaltrials.gov) - P=N/A | N=44 | Completed | Sponsor: Aristotle University Of Thessaloniki | Unknown status ➔ Completed | N=25 ➔ 44

Enrollment change • Real-world evidence • Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

FASTER-ACTING INSULIN ASPART VERSUS LISPRO OR REGULAR-ASPART IN MISSED BOLUS MITIGATION WITH THE MINIMED™ 780G SYSTEM: SUB-ANALYSIS OF A STANDARDIZED MEAL STUDY (ATTD 2026) - "In adults with T1D using MiniMed™ 780G, Fiasp showed a trend toward improved postprandial glycemia during missed bolus scenarios compared with lispro/aspart, without increased %TBR. These exploratory findings support further evaluation of ultra-rapid analogs in AHCL therapy."

Cross-cultural reliability and validity of the factors influencing adherence to standard precautions scale - Student version. (PubMed, Nurse Educ Pract) - "The Chinese FIASP-SV demonstrates satisfactory validity and reliability for assessing factors influencing SP adherence among nursing students and can be used as a reference to guide interventions to strengthen infection-control education and clinical safety."

Journal • Infectious Disease

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison chart: Some available insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System. (PubMed, J Diabetes Sci Technol) - "This study suggests that automated insulin and pramlintide systems have the potential to alleviate carbohydrate counting without degrading time in range. A longer and larger study is underway."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Comparison of the effectiveness of fast-acting insulin aspart with rapid-acting insulin analogues on glycaemic control: a retrospective cohort study using patient data from primary care practices in England. (PubMed, BMJ Open) - "Reductions in HbA1c were numerically larger with faster aspart in three of four subgroups. There was higher treatment persistency with faster aspart vs rapid-acting insulin analogues among T1D switchers."

Clinical • Journal • Retrospective data • Diabetes • Endocrine Disorders • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Sensor-Derived Glycemic Metrics in Women with Type 1 Diabetes Using Insulin Degludec Versus Other Basal Insulin Analogs During Pregnancy-A Post Hoc Analysis of the CopenFast Trial. (PubMed, Womens Health Rep (New Rochelle)) - "The use of faster-acting insulin aspart and insulin aspart was equally distributed in the two groups. Birthweight standard deviation score was 1.5 ± 1.2 versus 0.8 ± 1.1 (p = 0.01). In this post hoc analysis, pregnant women with type 1 diabetes using degludec achieved lower nighttime TIRp, experienced less severe hypoglycemia, and delivered infants who were heavier and thereby had less appropriate size compared with women using other basal insulin analogs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Aging with type 1 diabetes: a perspective on "octagenarians" living with type 1 diabetes in Italy (EASD 2025) - "Among patients treated with the conventional basal-bolus insulin regimen, most (76.5%) were treated with second-generation basal insulin (glargine U300 or degludec). The most used rapid insulin analogues were lispro (44%), aspart (32.4%), glulisine (10%), and faster aspart (11.9%)... Many people with type 1 diabetes have aged, becoming 'octogenarians' by being regularly followed up in Italian diabetes centers. The overall quality of care for patients regularly followed up has resulted in a lower-than-expected burden of end-stage renal disease, visual loss, and diabetic foot. Management of CV risk factors could be improved."

Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Cross-cultural reliability and validation of the Factors Affecting Compliance with Standard Precautions Scale-student version (ChiCTR) - P=N/A | N=480 | Completed | Sponsor: The Fifth Affiliated Hospital of Southern Medical University; The Fifth Affiliated Hospital of Southern Medical University

Compliance • New trial

A Pilot Study Evaluating Meal Timing, Macronutrient Composition, and Faster-Acting Insulin Aspart Versus Insulin Aspart on Postprandial Glycemia with the Medtronic Advanced Hybrid Closed-Loop System. (PubMed, Diabetes Technol Ther) - P | " For adults with type 1 diabetes who are susceptible to morning hyperglycemia, FiAsp delivered by AHCL and higher fat content of meals may help improve postprandial glycemic outcomes. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry-ACTRN12619001340123."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Cross-cultural adaptation and psychometric evaluation of the factors influencing adherence to the standard precautions scale - Student version (FIASP-SV) for Saudi Arabian nursing students. (PubMed, Int J Nurs Stud Adv) - "The FIASP-SV is a reliable and valid tool for assessing factors influencing nursing students' adherence to SPs in Saudi Arabia. This tool has significant implications for developing targeted educational interventions to improve SP practices among nursing students in Arabic-speaking contexts."

Journal • Infectious Disease

Intraperitoneal Insulin Partially Restores Growth Hormone Response to Hypoglycemia (ADA 2025) - "Participants fasted overnight before receiving ~40% of their total daily dose (TDD) Fiasp® through ultrasound-guided IP injection at 2 visits, and SQ injection at 1 visit... IP insulin partially restores growth hormone secretion and reduces peripheral insulin levels during hypoglycemia, potentially providing a therapeutic avenue for PwT1D prone to severe hypoglycemia."

Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

MiniMed 780G System Use with Fast-Acting Insulin Aspart by Adults with T1D (ADA 2025) - "These findings show that Fiasp is safe when used with MM780G AHCL and provides improved glycemic outcomes when compared to RAI with open-loop or HCL use."

Clinical • Metabolic Disorders • Severe Hypoglycemia

Efficacy of Ultra-rapid and Rapid-Acting Insulin Analogs in Hybrid and Advanced Automated Insulin Delivery Systems among People with Type 1 Diabetes—A Systematic Review and Meta-analysis of Randomized Controlled Trials (ADA 2025) - "Inclusion criteria were RCTs; T1D populations of any age; comparing URIAs (Fiasp® or Lyumjev®) with any type of RIAs; using any type of AID systems. URIAs safely improved glycemia and were comparable to RIAs among T1D people using AID systems. Despite outcomes demonstrating statistical significance, the clinical impact may be small, given the TIR improvement of 1.4% (registration ID: CRD42024578754)."

Metastases • Retrospective data • Review • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Faster-Acting Insulin Aspart around Continuous Moderate Intensity Exercise in Adults with Type 1 Diabetes—A Randomised Controlled Trial (ADA 2025) - "Participants maintained usual morning insulin degludec. Reduced insulin aspart or faster-acting aspart showed similar PD/PK characteristics around continuous moderate intensity cycling in adults with T1D."

Clinical • PK/PD data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Fully Closed-Loop Improves Glycemic Control Compared with Pump with CGM in Adolescents with Type 1 Diabetes and HbA1c Above Target: A Two-Center, Randomized Crossover Study. (PubMed, Diabetes Technol Ther) - "We evaluated the use of FCL with faster insulin aspart (Fiasp) in adolescents with T1D whose HbA1c was above recommended targets...No severe hypoglycemia or ketoacidosis occurred. FCL insulin delivery with CamAPS HX improved glucose outcomes compared with insulin pump therapy with CGM in adolescents with T1D and HbA1c above target."

Journal • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Comparing Medicare Maximum Fair Prices with Other Drug Prices in Other Countries (ISPOR 2025) - " The comparison showed that the costs of the 10 drugs included in the Part D negotiations (Januvia, Fiasp/NovoLog/NovoRapid insulin products, Farxiga/Forxiga, Enbrel, Jardiance, Xarelto, Eliquis, Entresto, Stelara, and Imbruvica) were still lower in other countries even after price negotiations. Despite substantial discounts provided by Medicare price negotiations, US maximum fair prices remain generally higher than prices applied in other countries with high healthcare spending per capita. A limitation of the analysis is the approximation of monthly drug costs without utilization data."

Medicare • Reimbursement • US reimbursement